Douglas Landy
Psychiatry · New City, NYNPI 1104893494
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,514 of the $14,754 with a category attached, or 84.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $5,536 and has fallen 75.1% since, to $1,380 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainsway USA Inc$2K
- AbbVie$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- plus $5K from 13 others
What the payments were for
- Speaking & faculty fees$2,12014%
- Food & beverage$12,51485%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainsway USA Inc | 1 | $2,120 |
| AbbVie | 79 | $1,774 |
| Alkermes, Inc. | 60 | $1,746 |
| Teva Pharmaceuticals USA, Inc. | 51 | $1,577 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,175 |
| Neurocrine Biosciences, Inc. | 38 | $1,070 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $880 |
| E.r. Squibb & Sons, L.L.C. | 28 | $845 |
| Vanda Pharmaceuticals Inc. | 28 | $648 |
| Johnson & Johnson | 17 | $644 |
| Sunovion Pharmaceuticals Inc. | 24 | $538 |
| Biogen | 5 | $408 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $347 |
| Corium, LLC | 19 | $338 |
| Lundbeck LLC | 15 | $259 |
| Supernus Pharmaceuticals, Inc. | 19 | $259 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $56 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,754 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 14 | $4,089 |
| Quetiapine Fumarate | 25 | $910 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 18 | $759 |
| Bupropion XlBupropion Hcl | 23 | $352 |
| Duloxetine Hcl | 18 | $334 |
| Clonazepam | 23 | $255 |
| Trazodone Hcl | 19 | $172 |
| Escitalopram Oxalate | 21 | $154 |
| Alprazolam | 19 | $146 |
| Fluoxetine Hcl | 35 | $108 |
| Zolpidem Tartrate | 11 | $34 |
| Hydrochlorothiazide | 13 | $10 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New City
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.